🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

One Final Vote for Jeff – We Appreciate You! Your daily votes for Jeff have been incredible! He's so close to winning John Holaday Bio-Health Leadership Award, Vote once per day, PLEASE cast one more vote: loom.ly/fu9fegI #biobuzz #addimmune #americangene

Today is National Women and Girls HIV/AIDS Awareness Day. The National HIV/AIDS Strategy provides a national strategy to accelerate efforts to end the #HIV epidemic by 2030. Click here to read a summary: bit.ly/3XmmufT #NWGHAAD

Public biotechs have raked in $10 billion this year, and the XBI is up over 50%! Gene therapy leaders are driving the momentum. loom.ly/tbdKi2Q #FOMO #biotech #investing Are you seeing this trend too? Let us know with a 👍

On this National Native HIV and AIDS Awareness Day (#NNHAAD), we're rallying behind a national movement to empower Native communities across the US and its territories to learn about the disease, get tested, join prevention efforts, and seek care for #HIV.

#ICYMI, our Chief Science Officer, Jeff Boyle, PhD, was featured in the 2024 March issue of Pharm Tech, providing commentary and insight on the development of Gamma-Delta T-cell therapies – and how we are leveraging #GeneTherapy. Read more: brnw.ch/21wI3Nx

Despite weak investment in 2023, new drug approvals reached a high with approvals in five gene therapies, weight loss & Alzheimer's. loom.ly/k0On_r0

The FDA approved Orchard Therapeutics - U.S. Lenmeldy for early juvenile metachromatic leukodystrophy! No treatment previously existed for this rare childhood genetic disease that leads to loss of motor & cognitive skill & eventually death. loom.ly/1PQPsBc loom.ly/1ONp2L4

R&D at the biggest biopharmaceuticals has increased quite a bit in 2023. Oncology, neuroscience and cardiovascular are some of the biggest areas where @astrazeneca, @Johnson&johnson, @novartis, @roche and @merck are spending. loom.ly/9C1kW2U

🚨 TONIGHT! - Mar 27th, 4PM EST🚨 Catch AGT's CEO, Jeff Galvin, on DC News Now's "Moco Minute." He'll discuss HIV research from AGT and its HIV division, Addimmune, the future of the biotech industry and pushing innovation. loom.ly/23ITaZc #AGT #Addimmune #MocoMinute

More signs of continued momentum in the biotech industry! Green shoots in IPO land with @boundlessbio following last month's Kyverna Therapeutics & @altoneuro's debut on the exchanges. ecDNA oncology company will launch $100 million IPO. loom.ly/BmtSpUM $BOLD $KYTX $ANRO

We are grateful to have Dr. Marcus Conant represent our mission to find a functional cure for #HIV, especially at #CROI2024. Learn about his journey in PharmaVoice: loom.ly/JV88YD0

Listen in with Dr. Marcus Conant as he discusses #genetherapy for HIV suppression with CGTLive here loom.ly/zllWHkQ

This #NYHAAD, we support Nat’l Youth HIV & AIDS Awareness Day (NYHAAD) and their mission to create meaningful and intentional spaces for young people to ask questions, learn, and talk about the impacts of HIV and their community. #StopHIVTogether #EndHIVStigma

The future of medicine! The strategic market insight company Nova 1 values the cell & gene therapy market @ $18 billion in 2023 growing at a CAGR of 18% over the next decade. They see a near $100 billion market size by 2033. loom.ly/kpuPhu4 #genetherapy #futureofmedicine

Dr. Marcus Conant will be participating in a roundtable on cell and #GeneTherapy alongside Andrew Dietz, MD, of @ShapeTX at this year’s CMO Summit 360 on April 18 at 12:50 PM ET. Learn more: loom.ly/EjJavXE #CMO360

Can genetic evidence make drugs more effective? A new study in Nature suggests YES. Drug mechanisms with genetic support have a 2.6x higher chance of success. loom.ly/NxSxjXk #genetics #science #healthcare

AGT CEO, Jeff Galvin, had a chat with HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Discover what lies ahead in our mission to find a cure for HIV! loom.ly/jAThqIU #HIVResearch #ClinicalTrials

M&A has been steady in 2024. We count 47 private & public deals to date totaling $53 billion. 15 have been >$1 billion with cancer, rare disease & cell therapies some of the areas of interest.

Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment. loom.ly/96TZ0jU #HIV #celltherapy #biotech

We've completed two clinical trials on our HIV CURE PROJECT with promising data. Now we need your help to try to take it to the finish line. Please consider donating today or sharing with someone who could. loom.ly/BioFNRo #HIVCure #HIV #Donate